Current aspects of the clinic, diagnosis and treatment of acquired myasthenia gravis (review). Part 1: diagnostics
https://doi.org/10.24884/1607-4181-2016-23-2-20-26
Abstract
Acquired myasthenia gravis is an autoimmune disease, based on the imbalance of humoral and cellular immunity, characterized by weakness and fatigue of skeletal muscles, and in some cases involvement of the heart muscle. In most cases, the object of the autoimmune destruction is peripheral nicotinic acetylcholine receptors of the postsynaptic membrane of the neuromuscular synapse. In myasthenia gravis there has been identified a number of other antigenic targets: muscle-specific tyrosine kinase, lowdensity lipoprotein receptor-related protein 4, titin, and ryanodine receptors skeletal muscles. Their specificity and pathogenetic role have been disclosed, but it is about 15-20% of seronegative forms that require further immunological research. Accurate diagnosis depends on the efficient detection of clinical forms of myasthenia gravis and full analysis of the autoimmune mechanisms underlying the disease.
About the Authors
S. N. Bardakov
S.M.Kirov Military Medical Academy;
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
S. A. Zhivolupov
S.M.Kirov Military Medical Academy;
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
E. R. Barantsevich
S.M.Kirov Military Medical Academy;
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
M. V. Zakharov
S.M.Kirov Military Medical Academy;
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
I. N. Samartsev
S.M.Kirov Military Medical Academy;
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Гехт Б. М. Синдромы патологической мышечной утомляемости. – М.: Медицина, 1974. – 200 с.
2. Ишмухаметова А. Т. и др. Эпидемиологическое исследование миастении гравис в Республике Башкортостан // Невролог. журн. –2006. – № 6 (11). – С. 16–21.
3. Неретин В. Я. и др. Эпидемиология миастении // Альманах клин. мед. – 2001. – № 4. – С. 178–179.
4. Панов А. Г., Догель Л. В., Лобзин В. С. Актуальные вопросы клиники миастении // Миастен. расстройства. – М.: Наука, 1965. – С. 140–146.
5. Романова Т. В., Повереннова И. Е. Клинико-эпидемиологическое исследование миастении в Самарской области // Мед. альманах. – 2011. – № 1. – С. 187–191.
6. Санадзе А. Г. и др. Антитела к мышцам (антититиновые антитела) у больных с поздним началом миастении: клинические и электрофизиологические корреляции // Невролог. журн. – 2003. – Прил. 1. – С 23–26.
7. Alkhawajah N., Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing // Muscle Nerve. – 2013. – № 48 (5). – Р. 705–710.
8. Alshekhlee A. et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals // Neurology. – 2009. – № 18 (72). – Р. 1548–1554.
9. Apel E. D. Rapsyn is required for MuSK signaling and recruits synaptic components to a MuSK-containing scaffold // Neuron. – 1997. – № 4 (18). – Р. 623–635.
10. Barth D. et al. Comparison of IVIg and PLEX in patients with myasthenia gravis / // Neurology. – 2011. – № 23 (76). – P. 2017–2023.
11. Benatar M. et al. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial // Ann N.-Y. Acad. Sci. – 2013. – № 1275. – Р. 17–22.
12. Bril V. et al. IVIg and PLEX in the treatment of myasthenia gravis // Ann N.-Y. Acad. Sci. – № 1275. – Р. 1–6.
13. Carr A. S. et al. A systematic review of population based epidemiological studies in myasthenia gravis // BMC Neurol. – 2010. – № 18 (10). – Р. 46–47.
14. Cruz P. M. R., Palace J., Beeson D. Inherited disorders of the neuromuscular junction: an update // J. Neurol. – 2014. – № 11 (261). – Р. 2234–2243.
15. DeChiara T. M. et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo // Cell. – 1996. – № 4 (85). – Р. 501–512.
16. Evoli A. et al. Juvenile myasthenia gravis with prepubertal onset // Neuromuscul Disord. – 1998. – № 8 (8). – Р. 561–567.
17. Higuchi O. et al. Autoantibodies to low-density lipoprotein receptor–related protein 4 in Myasthenia Gravis // Ann. Neurol. – 2011. – № 69 (2). – Р. 418–422.
18. Linton P. J., Dorshkind K. Age-related changes in lymphocyte development and function // Nat. Immunol. – 2004. – № 5 (2). – Р. 133–139.
19. Luebke E. et al. Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes // J. Neuroimmunol. – 1998. – № 1–2 (82). – Р. 98-108.
20. Marulli G. et al. Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis // J. Thorac. Cardiovasc. Surg. – 2013. – № 145 (3). – Р. 730–735.
21. Osserman K. E. Myasthenia gravis / K. E. Osserman. – N.-Y.: Grune and Stratton, 1958. – Р. 79–86.
22. Pasnoor M. et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience // Muscle Nerve. – 2005. – № 3 (41). – Р. 370–374.
23. Scarpino S. et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas // Clin. Exp. Immunol. – 2007. – № 149. – Р. 504–512.
24. Suzuki S. et al. Novel antibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis // J. Neuroimmunol. – 2005. – № 170. – P. 141–149.
25. Wolfe G. I. et al. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy // Ann. N.-Y. Acad. Sci. – 2003. – № 998. – Р. 473–480.
26. Wong S. H. et al. Ocular myasthenia gravis: controversies and updates // Curr. Neurol. Neurosci. Rep. – 2014. – № 14 (1). – Р. 421.
Review
For citations:
Bardakov S.N., Zhivolupov S.A., Barantsevich E.R., Zakharov M.V., Samartsev I.N. Current aspects of the clinic, diagnosis and treatment of acquired myasthenia gravis (review). Part 1: diagnostics. The Scientific Notes of the Pavlov University. 2016;23(2):20-26. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-2-20-26
Views:
1238
Email this article 